Connect Biopharma (CNTB) Corporate presentation summary

Rademikibart clinical development and efficacy

• Demonstrated efficacy and safety across multiple indications, including asthma, COPD, and atopic dermatitis, with global rights outside Greater China.

• Phase 2 studies in acute COPD and asthma exacerbations began in 2Q2025, with topline data expected mid-2026.

• U.S. FDA agreed rademikibart is ready for Phase 3 in chronic asthma and atopic dermatitis based on prior study results.

• Phase 3 AD study in China showed rapid, sustained efficacy through 52 weeks, with 87.1% IGA 0/1 and 96.6% EASI-75 responders.

• Safety profile comparable to placebo, with low rates of conjunctivitis and no significant drug-related safety issues in over 1,500 participants.

Mechanism of action and differentiation

• Rademikibart is a next-generation anti-IL-4Ra antibody, blocking both IL-4 and IL-13 signaling, with higher binding affinity and broader epitope engagement than dupilumab.

• Demonstrates faster onset, greater clinical response (FEV₁), and potential for less frequent dosing compared to dupilumab.

• Reduces eosinophil counts in asthma patients, unlike dupilumab, which increases them and is associated with higher rates of serious adverse events.

• Unique mechanism includes direct bronchodilation and reversal of IL-4/IL-13-induced β-agonist hyporesponsiveness, not observed with dupilumab.

Acute and chronic respiratory indications

• Acute and chronic asthma and COPD represent large, underserved markets, with millions of exacerbations annually in the US and EU.

• Rademikibart’s rapid FEV₁ improvement and IV formulation position it as a potential first-in-class acute treatment, with ongoing Phase 2 studies targeting urgent care, ED, and hospital settings.

• IV administration achieves faster and larger FEV₁ improvements than current therapies, with mean increases of 200–400 mL sustained through Day 29 in both asthma and COPD.

• No serious or severe adverse events observed in Phase 1 IV studies; safety profile supports further development.